Sir,
The July-September 2016 issue of the Indian J Psychiatry carried eight original articles. Of these, one [1] provided only a range of values for the age of the participants, and another [2] provided no description of the sample, at all. These are serious limitations of a manuscript because, without descriptive information about the sample, readers cannot know to what population the results of a study may be generalized.
Three other papers [3] [4] [5] presented data on age not as mean (standard deviation) values, but in class intervals or groups that were otherwise defined. This is completely illogical; age is a number, not a group. When continuous variables are categorized, precision is lost, and the ability of inferential statistical tests to identify statistical relationships is weakened. Continuous variables should be categorized only if there is a specific need, such as for administrative purposes, or when the data could not be accurately recorded, or when the distribution is skewed. [6, 7] Similar considerations apply to other continuous variables, as well; for example, education can be operationalized in units of years rather than as specific levels of attainment as presented by at least two teams of authors. [3, 5] Financial support and sponsorship Nil.
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How to cite this article: Andrade C. Age is a number, not a group. Indian J Psychiatry 2017;59:248. Olanzapine has poorer efficacy than risperidone for the treatment of the negative symptoms of schizophrenia with significantly greater improvements in negative symptom ratings at all follow-up visits, that is, at months 3, 6, 9, and 12.
It appears that the authors have completely misinterpreted the findings that they present in Table 3 in their paper. Although negative symptom ratings were numerically Sir, Suresh Kumar et al. [1] randomized patients with schizophrenia (n = 71) to receive either olanzapine (mean modal dose, 14.4 mg/day) or risperidone (mean modal dose, 5.5 mg/day) for 1 year. They reported that olanzapine was associated lower in the olanzapine group at each follow-up visit, the absolute change from baseline, which is what the authors studied in their statistical analysis, was actually greater in the risperidone group. This happened because the risperidone group had numerically more severe negative symptoms to begin with. The correct conclusion, therefore, is that olanzapine has poorer efficacy than risperidone for the treatment of the negative symptoms of schizophrenia, which is completely the opposite of what the authors stated in their title, abstract, results, discussion, and conclusions.
It is important that this error is recognized and recorded; else, it is likely that the paper will be highly cited to support a preference for olanzapine over risperidone for the attenuation of negative symptoms in the long-term management of schizophrenia.
The above notwithstanding, we do not believe that the new findings should be interpreted to support a preference for risperidone over olanzapine. This is because the negative symptom analysis was a part of the examination of many different outcome measures, and the statistical significance could have merely been a Type 1 error arising from the many statistical tests performed. In research, primary and secondary outcomes should be stated a priori, and greater emphasis should be laid on the former than on the latter. [2] There was no indication whatsoever that the authors [1] intended to study negative symptoms as their primary outcome.
As a final note, findings that are statistically significant are not necessarily clinically significant. In this study, the very small absolute differences for both negative symptoms and global ratings are an example in point.
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